Search
- Dec 11, 2023
Pyruvate kinase activation as a sickle cell disease strategy with Agios' CEO at #ASH23
Brian Goff highlights data from the phase 2 portion of the RISE UP pivotal study of Mitapivat for SCD that was presented at #ASH23 today.
- Jun 26, 2023
Agios on today’s phase 2 data for the pyruvate kinase activator mitapivat in sickle cell disease
Agios CEO Brian Goff on today's p2 SCD data and how he thinks maitapivat fits into the competitive landscape.